Skip to content

Abliva

Delivering mitochondrial health

  • English
    • English
    • Svenska
  • Abliva
    • This is Abliva
      • Delivering mitochondrial health
      • Orphan Drugs
    • Relevant publications
  • Mitochondrial Disease
    • Primary mitochondrial disease
      • MELAS-MIDD and KSS-CPEO
      • Leigh Syndrome
      • LHON
    • Patients
    • Expanded access policy
  • Research & Development
    • Portfolio
      • KL1333
      • NV354
      • Early programs
    • Clinical trials
      • The FALCON Study
  • Contact
    • Privacy policy

Press releases

  • All
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
All MARRegulatory
26 February, 2025
Regulatory

Notice of Extraordinary General Meeting in Abliva AB (publ)

At the request of Pharming Technologies B.V. (“Pharming”), a wholly-owned subsidiary of Pharming Group N.V., which, following its public offer to the shareholders of Abliva AB (publ) (“Abliva”), holds ...
Continue reading
9 December, 2024

Abliva Announces Publication of Results from Phase 1a/b Study of KL1333 in the Scientific Journal Brain

-Results demonstrated that KL1333 was safe and well tolerated, with early signs of efficacy in patients with primary mitochondrial disease- Abliva AB (Nasdaq Stockholm: ABLI) a clinical-stage company ...
Continue reading
16 September, 20249 December, 2024

Join Abliva for World Mitochondrial Disease Week 2024, September 16 – 22

-The company shares videos each day of the week to raise awareness about mitochondrial disease and to highlight ongoing activities at Abliva- Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage compa ...
Continue reading
18 July, 2024
Regulatory

Abliva Announces Positive Interim Analysis of the FALCON Study for KL1333 in Primary Mitochondrial Disease

-Independent committee confirms FALCON study is powered for potential success with both alternative endpoints passing futility- -Committee confirms strong safety profile of KL1333- -Abliva to hos ...
Continue reading
30 May, 2024

Abliva Announces Completion of 24 Weeks of Dosing in Wave 1 of the FALCON Study of KL1333 in Primary Mitochondrial Disease

-With 24 weeks of dosing complete, Abliva remains on track to report the interim analysis in early Q3 2024- Abliva AB (Nasdaq Stockholm: ABLI) a clinical-stage company developing medicines for [&helli ...
Continue reading
23 May, 2024
Regulatory

Resolutions from Annual General Meeting in Abliva AB (publ) on May 23, 2024

Abliva AB (Nasdaq Stockholm: ABLI) (”Abliva” or the ”Company”) today on May 23, 2024, held its Annual General Meeting (“AGM”). A summary of the resolution follows.
Continue reading
13 May, 2024

Abliva to Host Virtual KOL Event on KL1333 in Primary Mitochondrial Disease on May 21, 2024

Lund, Sweden, May 13, 2024 — Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage company developing drugs for the treatment of rare and severe primary mitochondrial disease, today announced that it w ...
Continue reading
22 April, 2024
Regulatory

Notice of Annual General Meeting of Abliva AB (publ)

The shareholders of Abliva AB (publ), corporate identity number 556595-6538, (“the Company or “Abliva”) are hereby convened to the Annual General Meeting, held at 1 p.m. on Thursday, 23 May 2024 at Me ...
Continue reading
26 March, 2024
Regulatory

Resolutions at the Extraordinary General Meeting in Abliva AB (publ)

Abliva AB (Nasdaq Stockholm: ABLI) (”Abliva” or the ”Company”) has today 26 March 2024 held an Extraordinary General Meeting. A summary of the resolutions follows. The resolutions were passed unanimou ...
Continue reading
22 February, 2024
Regulatory

Notice of Extraordinary General Meeting of Abliva AB (publ)

The shareholders of Abliva AB (publ), corporate identity number 556595-6538, (the “Company”), are hereby convened to the Extraordinary General Meeting (the “EGM”) to be held at 3 p.m. on Tuesday 26 Ma ...
Continue reading
20 December, 202319 February, 2024

Abliva Reaches Patient Enrollment Goal for Wave 1 of the FALCON Study

Abliva AB (Nasdaq Stockholm: ABLI) a clinical-stage company developing drugs for the treatment of rare and severe primary mitochondrial disease, today announced that the goal of enrolling 40 patients ...
Continue reading
14 December, 202319 February, 2024

Abliva Receives Orphan Designation from the European Commission for its Drug Candidate NV354

Abliva AB (Nasdaq Stockholm: ABLI) a clinical-stage company developing medicines for the treatment of rare and severe primary mitochondrial disease, today announced that the European Commission has gr ...
Continue reading

Posts navigation

Older posts
  1. Startpage

This is Abliva

  • Delivering mitochondrial health
  • Orphan Drugs
  • Relevant publications

Research & Development

  • Research & Development
  • KL1333
  • NV354
  • Early programs
  • The FALCON Study

Contact

Abliva AB (publ)
Medicon Village
223 81 Lund, Sweden

Phone
+46 (0)46-275 62 20

Generel questions
info@abliva.com

© Copyright 2020 – Abliva AB. All rights reserved. | We use cookies to improve our services | Cookie policy | Privacy policy

Cookies
We serve cookies. If you think that's ok, just click "Accept all". You can also choose what kind of cookies you want by clicking "Settings". Read our cookie policy
Settings Accept all
Cookies
Choose what kind of cookies to accept. Your choice will be saved for one year. Read our cookie policy
  • Necessary
    These cookies are not optional. They are needed for the website to function.
  • Statistics
    In order for us to improve the website's functionality and structure, based on how the website is used.
  • Experience
    In order for our website to perform as well as possible during your visit. If you refuse these cookies, some functionality will disappear from the website.
  • Marketing
    By sharing your interests and behavior as you visit our site, you increase the chance of seeing personalized content and offers.
Save Accept all